SAN DIEGO, May 11, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, a leader in Wnt signaling pathway research and development, today announced it will present preclinical data on the company’s investigational Wnt pathway inhibitor SM04646, currently being developed for the treatment of idiopathic pulmonary fibrosis (IPF), at the 2018 American Thoracic Society International Conference, to be held May 18-23, 2018 in San Diego, CA.
“We look forward to sharing our findings which highlight SM04646’s unique mechanism of action at this year’s ATS conference. We believe that SM04646 may eventually be used as monotherapy or in combination with currently approved and other pipeline medications to help fight idiopathic pulmonary fibrosis,” commented Dr. Yusuf Yazici, Chief Medical Officer of Samumed.
Poster Presentation Details:
|Abstract Title||Date/Time||Session Title|
|SM04646 Inhibited Wnt Pathway Gene Expression Stimulated in Response to Transforming Growth Factor-b and was Effective in a Chronic Model of Bleomycin-induced Pulmonary Fibrosis – Presentation #A5778/P305||Tuesday, May 22 11:15 a.m. – 1:00 p.m. PDT||C72 - Pulmonary Fibrosis: Mechanisms and Models|
Further details can be found on the ATS website at http://conference.thoracic.org/. A copy of the presentation materials can be accessed by visiting the Publications section of the Samumed website after the presentation concludes.
About the American Thoracic Society
Founded in 1905, the American Thoracic Society is the world's leading medical association dedicated to advancing pulmonary, critical care and sleep medicine. The Society's 15,000 members prevent and fight respiratory disease around the globe through research, education, patient care and advocacy. The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.
The ATS will hold its 2018 International Conference, May 18-23, in San Diego, California, where world-renowned experts will share the latest scientific research and clinical advances in pulmonary, critical care and sleep medicine.
SM04646 is a small molecule Wnt pathway inhibitor currently being developed for the treatment of idiopathic pulmonary fibrosis (IPF). Preclinical data on SM04646 has demonstrated anti-fibrotic properties in numerous in vitro and in vivo studies, including a bleomycin-induced model of pulmonary fibrosis where aerosolized SM04646 significantly reduced fibrosis in the lungs compared with vehicle. A Phase 1 study of SM04646 assessing the safety of the molecule is currently ongoing. Additional information on Samumed’s SM04646 IPF program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=19
Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases. Samumed’s clinical pipeline can be found here: https://www.samumed.com/pipeline/default.aspx
Matt Middleman, M.D.
LifeSci Public Relations